Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1

Biochemical and Biophysical Research Communications

Volumn 357, Issue 1, 2007, Pages 295-301

  Kaszubiak, Alexander ^a   Kupstat, Annette ^a   Müller, Ursula ^a   Hausmann, Romy ^a   Holm, Per Sonne ^b   Lage, Hermann ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gene regulation; MDR1; Multidrug resistance; RNAi; YB 1

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TETRACYCLINE; Y BOX BINDING PROTEIN 1;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENE VECTOR; GENETIC CODE; HUMAN; HUMAN CELL; MODULATION; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE;

CELL LINE, TUMOR; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NUCLEAR PROTEINS; P-GLYCOPROTEIN; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 34247140503     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.03.145     Document Type: Article

References (28)

1. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents 22 (2003) 188-199
2. Scotto K.W. Transcriptional regulation of ABC drug transporters. Oncogene 22 (2003) 7496-7511
3. Goldsmith M.E., Madden M.J., Morrow C.S., and Cowan K.H. A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J. Biol. Chem. 268 (1993) 5856-5860
4. Ohga T., Uchiumi T., Makino Y., Koike K., Wada M., Kuwano M., and Kohno K. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J. Biol. Chem. 273 (1998) 5997-6000
5. Hu Z., Jin S., and Scotto K.W. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J. Biol. Chem. 275 (2000) 2979-2985
6. Bargou R.C., Jurchott K., Wagener C., Bergmann S., Metzner S., Bommert K., Mapara M.Y., Winzer K.J., Dietel M., Dorken B., and Royer H.D. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 3 (1997) 447-450
7. Stein U., Jurchott K., Walther W., Bergmann S., Schlag P.M., and Royer H.D. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J. Biol. Chem. 276 (2001) 28562-28569
8. Fujita T., Ito K., Izumi H., Kimura M., Sano M., Nakagomi H., Maeno K., Hama Y., Shingu K., Tsuchiya S., Kohno K., and Fujimori M. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin. Cancer Res. 11 (2005) 8837-8844
9. Janz M., Harbeck N., Dettmar P., Berger U., Schmidt A., Jurchott K., Schmitt M., and Royer H.D. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer 97 (2002) 278-282
10. Oda Y., Ohishi Y., Saito T., Hinoshita E., Uchiumi T., Kinukawa N., Iwamoto Y., Kohno K., Kuwano M., and Tsuneyoshi M. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J. Pathol. 199 (2003) 251-258
11. Saji H., Toi M., Saji S., Koike M., Kohno K., and Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett. 190 (2003) 191-197
12. Vaiman A.V., Stromskaya T.P., Rybalkina E.Y., Sorokin A.V., Guryanov S.G., Zabotina T.N., Mechetner E.B., Ovchinnikov L.P., and Stavrovskaya A.A. Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells. Biochemistry (Mosc.) 71 (2006) 146-154
13. Dietel M., Arps H., Lage H., and Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50 (1990) 6100-6106
14. Lage H., and Dietel M. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J. Cancer Res. Clin. Oncol. 128 (2002) 349-357
15. Lage H. Molecular analysis of therapy resistance in gastric cancer. Dig. Dis. 21 (2003) 326-338
16. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
17. Harborth J., Elbashir S.M., Bechert K., Tuschl T., and Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J. Cell Sci. 114 (2001) 4557-4565
18. Muratovska A., and Eccles M.R. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558 (2004) 63-68
19. Nieth C., Priebsch A., Stege A., and Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545 (2003) 144-150
20. Materna V., Stege A., Surowiak P., Priebsch A., and Lage H. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem. Biophys. Res. Commun. 348 (2006) 153-157
21. Priebsch A., Rompe F., Tönnies H., Kowalski P., Surowiak P., Stege A., Materna V., and Lage H. Complete reversal of ABCG2-depending atypical multidrug resistance (MDR) by RNA interference in human carcinoma cells. Oligonucleotides 16 (2006) 263-274
22. Stege A., Priebsch A., Nieth C., and Lage H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther. 11 (2004) 699-706
23. van de Wetering M., Oving I., Muncan V., Tjon Pon Fong M., Brantjes H., van Leenen D., Holstege F.C.P., Brummelkamp T.R., Agami R., and Clevers H. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 4 (2003) 609-615
24. Alam J., and Cook J.L. Reporter genes: application to the study of mammalian gene transcription. Anal. Biochem. 188 (1990) 245-254
25. A. Kaszubiak, P.S. Holm, H. Lage, Overcoming the classical multidrug resistance (MDR) phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes, Int. J. Oncol., in press.
26. Schittek B., Psenner K., Sauer B., Meier F., Iftner T., and Garbe C. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int. J. Cancer (2007) (Epub ahead of print)
27. Lasham A., Moloney S., Hale T., Homer C., Zhang Y.F., Murison J.G., Braithwaite A.W., and Watson J. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J. Biol. Chem. 278 (2003) 35516-35523
28. Kohno K., Izumi H., Uchiumi T., Ashizuka M., and Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25 (2003) 691-698